Conduit Pharmaceuticals (CDT) Institutional Ownership $4.72 -1.03 (-17.91%) Closing price 04:00 PM EasternExtended Trading$4.80 +0.08 (+1.59%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Conduit Pharmaceuticals (NASDAQ:CDT)CurrentInstitutional OwnershipPercentage3.29%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$160.19MNumber ofInstitutional Sellers(last 12 months)0 Get CDT Insider Trade Alerts Want to know when executives and insiders are buying or selling Conduit Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Conduit Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Citadel Advisors LLC526,268$36K0.0%+177.0%51.094% 2/13/2025 Barclays PLC892,350$61K0.0%+6.5%86.636% 2/12/2025 Geode Capital Management LLC584,984$40K0.0%+36.8%56.795% 1/30/2025 Rhumbline Advisers1,028,702$71K0.0%+5,034.0%1.000% (Data available from 1/1/2016 forward) CDT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CDT shares? During the previous two years, the following institutional investors and hedge funds held shares of Conduit Pharmaceuticals shares: Rhumbline Advisers ($71K), Barclays PLC ($61K), and Geode Capital Management LLC ($40K), Citadel Advisors LLC ($36K).Learn more on CDT's institutional investors. What percentage of Conduit Pharmaceuticals stock is owned by institutional investors? 3.29% of Conduit Pharmaceuticals stock is owned by institutional investors. Learn more on CDT's institutional investor holdings. Which institutional investors have been buying Conduit Pharmaceuticals stock? The following institutional investors have purchased Conduit Pharmaceuticals stock in the last 24 months: Rhumbline Advisers ($1.01M), Citadel Advisors LLC ($336.28K), Geode Capital Management LLC ($157.31K), and Barclays PLC ($54.52K). How much institutional buying is happening at Conduit Pharmaceuticals? Institutional investors have bought a total of 1,556,773 shares in the last 24 months. This purchase volume represents approximately $160.19M in transactions. Related Companies Chemomab Therapeutics Major Shareholders AlloVir Major Shareholders Allarity Therapeutics Major Shareholders TherapeuticsMD Major Shareholders Bullfrog AI Major Shareholders GlycoMimetics Major Shareholders ProMIS Neurosciences Major Shareholders Synergy CHC Corp. (Uplisting) Major Shareholders Cingulate Major Shareholders Lipocine Major Shareholders This page (NASDAQ:CDT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDT Stock Free CDT Stock Alerts